E D'Amico1, A Zanghì1, M Sciandra2, G Borriello3, G Callari4, A Gallo5, G Salemi6, S Cottone7, M Buccafusca8, P Valentino9, R B Bossio10, L M E Grimaldi11, C Pozzilli3, G Tedeschi5, M Zappia1, F Patti12. 1. Department "G.F. Ingrassia", MS centre University of Catania, Catania, Italy. 2. Department of Economics, Business and Statistics, University of Palermo, Palermo, Italy. 3. University of Rome "La Sapienza"-S. Andrea Hospital, Rome, Italy. 4. Institute Foundation "G. Giglio", Cefalù, Italy. 5. University "Federico II"-I Neurologic Clinic, Naples, Italy. 6. Policlinico "P. Giaccone", Palermo, Italy. 7. Villa Sofia Cervello Hospital, Palermo, Italy. 8. Azienda Ospedaliera Universitaria "G. Martino", Messina, Italy. 9. Azienda Ospedaliera Universitaria "Mater Domini", Catanzaro, Italy. 10. Azienda Sanitaria Provinciale U. O. di Neurologia, Cosenza, Italy. 11. Institute Foundation "G. Giglio ", Cefalù, Italy. 12. Department "G.F. Ingrassia", MS centre University of Catania, Catania, Italy. patti@unict.it.
Abstract
BACKGROUND: Teriflunomide (TRF) and Dimethyl fumarate (DMF) are licensed drugs for relapsing-remitting Multiple Sclerosis (RRMS). OBJECTIVES: We aimed to compare the rate and the time to discontinuation among persons with RRMS (pwRRMS), newly treated with TRF and DMF. MATERIALS AND METHODS: A retrospective study on prospectively collected data was performed in nine tertiary MS centers, in Italy. The 24-month discontinuation rate in the two cohorts was the primary study outcome. We also assessed the time to discontinuation and reasons of therapy withdrawn. Discontinuation of TRF and DMF was defined as a gap of treatment ≥ 60 days. RESULTS: A cohort of 903 pwRRMS (316 on TRF and 587 on DMF) was analyzed. During 24 months of follow-up, pwRRMS on TRF and DMF showed similar discontinuation rates. The analysis of predictors with Cox regression model showed differences between the two groups (p for log-rank test = 0.007); male gender [HR 2.21 (1.00-4.90); p = 0.01] and the number of previous switches [HR 1.47 (1.16-1.86); p = 0.01] were associated with higher hazard of discontinuation in the DMF group. CONCLUSIONS: In a real-world setting, pwRRMS on TRF and DMF had similar discontinuation rates over 24 months. Male pwRRMS on DMF with a previous history of therapeutic failure are at more risk of discontinuation therapy.
BACKGROUND:Teriflunomide (TRF) and Dimethyl fumarate (DMF) are licensed drugs for relapsing-remitting Multiple Sclerosis (RRMS). OBJECTIVES: We aimed to compare the rate and the time to discontinuation among persons with RRMS (pwRRMS), newly treated with TRF and DMF. MATERIALS AND METHODS: A retrospective study on prospectively collected data was performed in nine tertiary MS centers, in Italy. The 24-month discontinuation rate in the two cohorts was the primary study outcome. We also assessed the time to discontinuation and reasons of therapy withdrawn. Discontinuation of TRF and DMF was defined as a gap of treatment ≥ 60 days. RESULTS: A cohort of 903 pwRRMS (316 on TRF and 587 on DMF) was analyzed. During 24 months of follow-up, pwRRMS on TRF and DMF showed similar discontinuation rates. The analysis of predictors with Cox regression model showed differences between the two groups (p for log-rank test = 0.007); male gender [HR 2.21 (1.00-4.90); p = 0.01] and the number of previous switches [HR 1.47 (1.16-1.86); p = 0.01] were associated with higher hazard of discontinuation in the DMF group. CONCLUSIONS: In a real-world setting, pwRRMS on TRF and DMF had similar discontinuation rates over 24 months. Male pwRRMS on DMF with a previous history of therapeutic failure are at more risk of discontinuation therapy.
Authors: Hans-Georg Eichler; Eric Abadie; Alasdair Breckenridge; Bruno Flamion; Lars L Gustafsson; Hubert Leufkens; Malcolm Rowland; Christian K Schneider; Brigitte Bloechl-Daum Journal: Nat Rev Drug Discov Date: 2011-07-01 Impact factor: 84.694
Authors: Robert J Fox; David H Miller; J Theodore Phillips; Michael Hutchinson; Eva Havrdova; Mariko Kita; Minhua Yang; Kartik Raghupathi; Mark Novas; Marianne T Sweetser; Vissia Viglietta; Katherine T Dawson Journal: N Engl J Med Date: 2012-09-20 Impact factor: 91.245
Authors: Ralf Gold; Ludwig Kappos; Douglas L Arnold; Amit Bar-Or; Gavin Giovannoni; Krzysztof Selmaj; Carlo Tornatore; Marianne T Sweetser; Minhua Yang; Sarah I Sheikh; Katherine T Dawson Journal: N Engl J Med Date: 2012-09-20 Impact factor: 91.245
Authors: Christian Confavreux; Paul O'Connor; Giancarlo Comi; Mark S Freedman; Aaron E Miller; Tomas P Olsson; Jerry S Wolinsky; Teresa Bagulho; Jean-Luc Delhay; Deborah Dukovic; Philippe Truffinet; Ludwig Kappos Journal: Lancet Neurol Date: 2014-01-23 Impact factor: 44.182
Authors: Chris H Polman; Stephen C Reingold; Brenda Banwell; Michel Clanet; Jeffrey A Cohen; Massimo Filippi; Kazuo Fujihara; Eva Havrdova; Michael Hutchinson; Ludwig Kappos; Fred D Lublin; Xavier Montalban; Paul O'Connor; Magnhild Sandberg-Wollheim; Alan J Thompson; Emmanuelle Waubant; Brian Weinshenker; Jerry S Wolinsky Journal: Ann Neurol Date: 2011-02 Impact factor: 10.422
Authors: Paul O'Connor; Giancarlo Comi; Mark S Freedman; Aaron E Miller; Ludwig Kappos; Jean-Pierre Bouchard; Christine Lebrun-Frenay; Jan Mares; Myriam Benamor; Karthinathan Thangavelu; Jinjun Liang; Philippe Truffinet; Victoria J Lawson; Jerry S Wolinsky Journal: Neurology Date: 2016-02-10 Impact factor: 9.910
Authors: J Theodore Phillips; April A Erwin; Stephanie Agrella; Marcelo Kremenchutzky; John F Kramer; Malcolm J M Darkes; Jonathan Kendter; Heather Abourjaily; Jitesh Rana; Robert J Fox Journal: Neurol Ther Date: 2015-11-02
Authors: Jennifer H Yang; Torge Rempe; Natalie Whitmire; Anastasie Dunn-Pirio; Jennifer S Graves Journal: Front Neurol Date: 2022-06-03 Impact factor: 4.086
Authors: Paulus S Rommer; Ron Milo; May H Han; Sammita Satyanarayan; Johann Sellner; Larissa Hauer; Zsolt Illes; Clemens Warnke; Sarah Laurent; Martin S Weber; Yinan Zhang; Olaf Stuve Journal: Front Immunol Date: 2019-07-11 Impact factor: 7.561
Authors: Jiwon Oh; Sandra Vukusic; Klaus Tiel-Wilck; Jihad Said Inshasi; David Rog; Darren P Baker; Yelena Pyatkevich; Elizabeth M Poole; Patrick Vermersch Journal: J Cent Nerv Syst Dis Date: 2021-07-29
Authors: Michael Guger; Michael Matthias Ackerl; Martin Heine; Christiane Hofinger-Renner; Heinrich Karl Spiss; Andrea Taut; Karin Unger; Fritz Leutmezer Journal: eNeurologicalSci Date: 2022-03-07